Short Interest in Catheter Precision, Inc. (NYSEAMERICAN:VTAK) Increases By 153.3%

Catheter Precision, Inc. (NYSEAMERICAN:VTAK) saw a significant increase in short interest in the month of May. As of May 29th, there was short interest totaling 46,045 shares, an increase of 153.3% from the May 14th total of 18,181 shares. Approximately 1.8% of the company’s shares are sold short. Based on an average daily volume of 130,709 shares, the short-interest ratio is currently 0.4 days.

Institutional Investors Weigh In On Catheter Precision

A hedge fund recently bought a new stake in Catheter Precision stock. Millennium Management LLC acquired a new position in Catheter Precision, Inc. (NYSEAMERICAN:VTAK) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 34,721 shares of the company’s stock, valued at approximately $64,000. Millennium Management LLC owned approximately 2.08% of Catheter Precision as of its most recent SEC filing. Hedge funds and other institutional investors own 20.34% of the company’s stock.

Catheter Precision Trading Down 1.9%

NYSEAMERICAN:VTAK traded down $0.02 during trading hours on Friday, reaching $1.05. 23,079 shares of the company were exchanged, compared to its average volume of 100,020. The company has a debt-to-equity ratio of 0.35, a current ratio of 0.06 and a quick ratio of 0.06. The firm has a market cap of $2.82 million, a price-to-earnings ratio of -0.08 and a beta of -1.01. Catheter Precision has a 52-week low of $0.75 and a 52-week high of $8.50. The stock has a 50 day simple moving average of $0.94 and a 200 day simple moving average of $1.52.

Catheter Precision (NYSEAMERICAN:VTAK) last posted its quarterly earnings results on Monday, May 18th. The company reported ($1.39) earnings per share for the quarter, topping analysts’ consensus estimates of ($20.90) by $19.51. The company had revenue of $0.43 million for the quarter, compared to the consensus estimate of $1.60 million. Catheter Precision had a negative net margin of 1,297.56% and a negative return on equity of 76.51%.

About Catheter Precision

Catheter Precision, Inc (NYSE American: VTAK) is a medical device company specializing in the design, development and manufacture of catheter-based products for interventional cardiology and peripheral vascular procedures. The company’s core business centers on balloon catheter platforms, offering both standard and specialty catheter configurations that address applications ranging from percutaneous transluminal angioplasty (PTA) to percutaneous transluminal coronary angioplasty (PTCA). Catheter Precision’s product portfolio is engineered to meet diverse clinical needs, including high-pressure dilation, scored and cutting balloon therapies, and drug-coated balloon delivery.

All of Catheter Precision’s products are developed in its ISO 13485-certified, FDA-registered manufacturing facility in Bloomington, Minnesota.